Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one randomized controlled trial. ^[1]
• Papzimeos (zopapogene imadenovec-drba) is indicated for the treatment of adults with recurrent respiratory papillomatosis (RRP).
• Among 35 adults (≥18 years) with RRP requiring ≥3 interventions in the prior year, 18 patients (51%) treated at the recommended phase 2 dose of 5×10¹¹ particle units achieved a complete response, defined as no intervention required for 12 months after treatment.
• The median duration of complete response was not reached at the time of reporting, indicating sustained responses.
• In adults aged ≥18 years with RRP requiring ≥3 interventions in the prior year, treatment-related adverse events were primarily mild, with injection site reaction in 34/35 patients (97%), fatigue in 28/35 (80%), chills in 25/35 (71%), and fever in 24/35 (69%). No significant safety concerns or severe adverse effects were reported; adverse events were grades 1–2.
• There is no population type or subgroup information available in the reviewed studies.